- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01187901
A Clinical Trial of COX and EGFR Inhibition in Familial Polyposis Patients (FAPEST)
Genetic Events Leading to APC-Dependent Colon Cancer in High-Risk Families; a Clinical Trial of COX and EGFR Inhibition in Familial Polyposis Patients
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This will be a single-center, phase-II, six-month-long, placebo-controlled, double blinded, randomized trial of the epidermal growth factor receptor (EGFR) inhibitor, erlotinib (Tarceva) and the cyclooxygenase (COX-2) inhibitor, sulindac in patients with familial adenomatous polyposis (FAP) or attenuated FAP. FAP is an autosomal dominant inherited colon cancer predisposition with a 100% risk of colon cancer in the absence of preventive care (endoscopy and surgery). Efficacious chemoprevention for duodenal adenomas is an unmet clinical need in FAP patients that would reduce the morbidity from duodenectomy and risk of duodenal adenocarcinoma. Currently the only Food and Drug Administration (FDA)-approved chemopreventive agent is celecoxib which results in a modest reduction of duodenal and colorectal polyps and is associated with cardiac toxicity at effective doses. If it can be shown that combinatorial inhibition of COX-2 and EGFR activity leads to successful regression in duodenal adenomatous polyps in FAP, it could be used as an effective chemopreventive regimen in FAP patients with duodenal adenomas or who have undergone surgical resection of duodenal adenomas or have many rectal adenomas. FAP and AFAP patients will be screened by endoscopy for presence of 5 or more duodenal polyps, then randomized to either A) erlotinib at 75 mg/day and sulindac at 150 mg/day or B) placebo for 6 months. The endpoint will be endoscopy at 6 months.
Primary Aim : To determine if the combination of sulindac and erlotinib causes a significant regression of duodenal polyp burden at 6 mohths in FAP and attenuated FAP patients.
Secondary Aim: To measure if combination of sulindac and erlotinib cause a reduction in total duodenal polyp count, and change in duodenal polyp burden or count stratified by genotype and initial polyp burden.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Utah
-
Salt Lake City, Utah, United States, 84112
- Huntsman Cancer Institute
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients who are 18 years or older with a clinical or genetic diagnosis of FAP or attenuated FAP.
- Presence of duodenal polyps with a sum of diameters ≥ 5mm.
- Minimum of two weeks since any major surgery
- WHO performance status ≤1
- Adequate bone marrow function as show by: normal leukocyte count, platelet count ≥ 120 x 109/L, Hgb > 12 g/dL
- Adequate liver function as shown by: normal serum bilirubin(≤ 1.5 Upper Limit Normal {ULN}) and serum transaminases (≤ 2.0 ULN)
- Patient must discontinue taking any Nonsteroidal anti-inflammatory drugs (NSAIDS) within one month of treatment initiation.
- Patients must be able to provide written informed consent.
Exclusion Criteria:
- Prior treatment with any investigational drug within the preceding 4 weeks.
- Malignancies within the past 3 years except for adequately treated carcinoma of the cervix or basal or squamous cell carcinomas of the skins.
Patients who have any severe and/or uncontrolled medical conditions or other conditions that could affect their participation in the study as determined by the Principal Investigator such as:
- Unstable angina pectoris, symptomatic congestive heart failure, myocardial infarction ≤ 6 months prior to first study treatment, serious uncontrolled cardiac arrhythmia
- Severely impaired lung function
- Any active (acute or chronic) or uncontrolled infection/ disorders.
- Nonmalignant medical illnesses that are uncontrolled or whose control may be jeopardized by the treatment with the study therapy
- Liver disease such as cirrhosis, chronic active hepatitis or chronic persistent hepatitis
Screening clinical laboratory values that indicate any of the following:
- anemia
- thrombocytopenia
- leucopenia
- elevations of transaminases greater than 2X ULN
- elevation of bilirubin > 1.5 X ULN
- alkaline phosphatase elevation > 1.5 X ULN
- increased creatinine, urinary protein, or urinary casts outside the clinically normal range.
- Gastrointestinal bleeding (symptoms including dyspnea, fatigue, angina, weakness, malaise, melena, hematochezia, hematemesis, anemia or abdominal pain will require clinical assessment to rule out gastrointestinal bleeding).
- Patient who is currently taking any anti-coagulation medication.
- Women who are pregnant or breast feeding.
- Patients with a known hypersensitivity to sulindac or erlotinib or to their excipients
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Erlotinib and Sulindac
Erlotinib 75 mg per day in combination with sulindac 150 mg twice daily for 6 months.
|
Tarceva oral tablets are conventional, immediate-release tablets containing erlotinib as the hydrochloride salt.
Erlotinib(75mg)will be taken once daily for six months in combination with sulindac.
Other Names:
Sulindac is a non-steroidal, anti-inflammatory indene derivative designed for the treatment of arthritic conditions.
For this study, sulindac (150mg) will be taken twice daily in combination with erlotinib
Other Names:
|
Placebo Comparator: Placebo A and Placebo B
Placebo capsules matching erlotinib active comparator (Placebo A) once daily and placebo capsules matching sulindac active comparator (Placebo B) twice daily for 6 months
|
Erlotinib (Tarceva) will provide a 25 mg identical placebo.
This will be provided by the Division of Cancer Prevention at the NIH who will receive the drug and placebo from the manufacturer, OSI/Genentech.
Dosage for Placebo A will be 75 mg a day for 6 months.
Other Names:
Sulindac will be encapsulated in 150 mg doses along with an identical encapsulated Placebo B. One 150 mg capsules of Placebo B will be taken twice per day with meals (breakfast and supper).
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Duodenal Polyp Burden From Baseline to 6 Months
Time Frame: Baseline and 6 months
|
A comparison between the Sulindac-erlotinib and Placebo arms of the change in polyp burden from a 10-centimeter segment of the duodenum, measured as the sum of the diameters of the polyps, in millimeters (mm), from the duodenal segment (6-month polyp burden minus baseline polyp burden).
|
Baseline and 6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Duodenal Polyp Burden From Baseline to 6 Months in Classic Familial Adenomatous Polyposis (FAP) Participants
Time Frame: Baseline and 6 months
|
A comparison between the Sulindac-erlotinib and Placebo arm Classic FAP subgroups of the change in polyp burden from a 10-centimeter segment of the duodenum, measured as the sum of the diameters of the polyps, in millimeters (mm), from the duodenal segment (6-month polyp burden minus baseline polyp burden).
|
Baseline and 6 months
|
Change in Duodenal Polyp Burden From Baseline to 6 Months in Attenuated FAP Participants
Time Frame: Baseline and 6 months
|
A comparison between the Sulindac-erlotinib and Placebo arm Attenuated FAP subgroups of the change in polyp burden from a 10-centimeter segment of the duodenum, measured as the sum of the diameters of the polyps, in millimeters (mm), from the duodenal segment (6-month polyp burden minus baseline polyp burden).
|
Baseline and 6 months
|
Change in Number of Duodenal Polyps From Baseline to 6 Months
Time Frame: Baseline and 6 months
|
A comparison between the Sulindac-erlotinib and Placebo arms of the change in number of polyps in a 10-centimeter segment of the duodenum (6-month polyp count minus baseline polyp count).
|
Baseline and 6 months
|
Change in Number of Duodenal Polyps From Baseline to 6 Months in Classic FAP Participants
Time Frame: Baseline and 6 months
|
A comparison between the Sulindac-erlotinib and Placebo arm Classic FAP subgroups of the change in number of polyps in a 10-centimeter segment of the duodenum (6-month polyp count minus baseline polyp count)
|
Baseline and 6 months
|
Change in Number of Duodenal Polyps From Baseline to 6 Months in Attenuated FAP Participants
Time Frame: Baseline and 6 months
|
A comparison between the Sulindac-erlotinib and Placebo arm Attenuated FAP subgroups of the change in number of polyps in a 10-centimeter segment of the duodenum (6-month polyp count minus baseline polyp count)
|
Baseline and 6 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Chair: Randall Burt, MD, University of Utah at Huntsman Cancer Institute
- Principal Investigator: Niloy J Samadder, MD, University of Utah at Huntsman Cancer Institute
Publications and helpful links
General Publications
- Sample DC, Samadder NJ, Pappas LM, Boucher KM, Samowitz WS, Berry T, Westover M, Nathan D, Kanth P, Byrne KR, Burt RW, Neklason DW. Variables affecting penetrance of gastric and duodenal phenotype in familial adenomatous polyposis patients. BMC Gastroenterol. 2018 Jul 16;18(1):115. doi: 10.1186/s12876-018-0841-8.
- Samadder NJ, Kuwada SK, Boucher KM, Byrne K, Kanth P, Samowitz W, Jones D, Tavtigian SV, Westover M, Berry T, Jasperson K, Pappas L, Smith L, Sample D, Burt RW, Neklason DW. Association of Sulindac and Erlotinib vs Placebo With Colorectal Neoplasia in Familial Adenomatous Polyposis: Secondary Analysis of a Randomized Clinical Trial. JAMA Oncol. 2018 May 1;4(5):671-677. doi: 10.1001/jamaoncol.2017.5431.
- Samadder NJ, Neklason DW, Boucher KM, Byrne KR, Kanth P, Samowitz W, Jones D, Tavtigian SV, Done MW, Berry T, Jasperson K, Pappas L, Smith L, Sample D, Davis R, Topham MK, Lynch P, Strait E, McKinnon W, Burt RW, Kuwada SK. Effect of Sulindac and Erlotinib vs Placebo on Duodenal Neoplasia in Familial Adenomatous Polyposis: A Randomized Clinical Trial. JAMA. 2016 Mar 22-29;315(12):1266-75. doi: 10.1001/jama.2016.2522.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Neoplasms, Glandular and Epithelial
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Gastrointestinal Diseases
- Genetic Diseases, Inborn
- Pharyngeal Neoplasms
- Otorhinolaryngologic Neoplasms
- Head and Neck Neoplasms
- Nasopharyngeal Diseases
- Pharyngeal Diseases
- Stomatognathic Diseases
- Otorhinolaryngologic Diseases
- Colonic Diseases
- Intestinal Diseases
- Intestinal Neoplasms
- Rectal Diseases
- Neoplastic Syndromes, Hereditary
- Adenomatous Polyps
- Adenoma
- Intestinal Polyposis
- Nasopharyngeal Neoplasms
- Colorectal Neoplasms
- Adenomatous Polyposis Coli
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Cyclooxygenase Inhibitors
- Antineoplastic Agents
- Protein Kinase Inhibitors
- Erlotinib Hydrochloride
- Sulindac
Other Study ID Numbers
- 00039278
- P01CA073992 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Adenomatous Polyposis Coli
-
Assistance Publique - Hôpitaux de ParisAxcan PharmaUnknownAdenomatous Polyposis Coli, FamilialFrance
-
Fondazione IRCCS Istituto Nazionale dei Tumori,...CompletedFamilial Adenomatous Polyposis (FAP)Italy
-
S.L.A. Pharma AGCompletedFAP | Familial Adenomatous Polyposis ColiUnited Kingdom
-
Dr. Ersin Arslan Education and Training HospitalCompleted
-
Yonsei UniversityCompletedFamilial Adenomatous PolyposisKorea, Republic of
-
London North West Healthcare NHS TrustUnknownFamilial Adenomatous PolyposisUnited Kingdom
-
M.D. Anderson Cancer CenterCompletedAttenuated Familial Adenomatous Polyposis | Deleterious Familial Adenomatous PolyposisUnited States
-
Vanderbilt University Medical CenterEnrolling by invitationFamilial Adenomatous PolyposisUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedFamilial Adenomatous PolyposisUnited States
-
National Cancer Institute (NCI)CompletedFamilial Adenomatous PolyposisUnited States
Clinical Trials on Erlotinib
-
National Cancer Institute (NCI)University of Chicago; City of Hope Medical Center; University of Southern California and other collaboratorsCompleted
-
AVEO Pharmaceuticals, Inc.Biodesix, Inc.TerminatedNon-small Cell Lung CancerKorea, Republic of, United States, Australia, Taiwan, Singapore, Hong Kong, Italy
-
M.D. Anderson Cancer CenterCompletedAdvanced CancersUnited States
-
PfizerCompletedCarcinoma, Non-Small-Cell LungUnited States
-
Fox Chase Cancer CenterMillennium Pharmaceuticals, Inc.TerminatedNon-small Cell Lung Cancer Metastatic | Non-small Cell Lung Cancer RecurrentUnited States
-
University of ChicagoNational Cancer Institute (NCI)CompletedMalignant Peritoneal MesotheliomaUnited States
-
Grupo de Investigación Clínica en Oncología RadioterapiaCompletedSquamous Cell Carcinoma of the Head and NeckSpain
-
Kyowa Kirin Co., Ltd.TerminatedNon-small-cell Lung CancerJapan
-
Merck Sharp & Dohme LLCCompleted
-
Duke UniversityBristol-Myers Squibb; Genentech, Inc.Completed